Related Experiment Videos
Signalling pathways as targets for anticancer drug development
1Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson 85724.
Abstract:
Intracellular signalling pathways mediating the effects of oncogenes on cell growth and transformation offer novel targets for the development of anticancer drugs. With this approach, it may be sufficient to target a component of the signalling pathway activated by the oncogene rather than the oncogene product itself. In this review, the abilities of some antiproliferative drugs to inhibit signalling targets are considered. There are some anticancer drugs already in clinical trial that may act by inhibiting signalling targets, as well as drugs in preclinical development. Some problems that may be encountered in developing this new class of anticancer drugs are discussed.
Insights
Targeting intracellular signaling pathways activated by oncogenes offers a new strategy for anticancer drug development. This review examines drugs that inhibit these pathways, including those in clinical trials and preclinical development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Oncogenes drive cell growth and transformation through intracellular signaling pathways.
- Targeting these pathways presents a promising strategy for novel anticancer drug development.
- Inhibiting specific signaling components may be more effective than targeting oncogene products directly.
Purpose of the Study:
- To review the potential of targeting intracellular signaling pathways for anticancer drug development.
- To examine existing and emerging antiproliferative drugs that inhibit signaling targets.
- To discuss challenges in developing this new class of anticancer therapeutics.
Main Methods:
- Literature review of scientific publications.
- Analysis of existing antiproliferative drugs and their mechanisms of action.
- Evaluation of drugs in clinical trials and preclinical development targeting signaling pathways.
Main Results:
- Several antiproliferative drugs demonstrate the ability to inhibit key signaling targets.
- Anticancer drugs targeting signaling pathways are progressing through clinical trials and preclinical development.
- The review identifies specific signaling pathways and their targeted inhibitors.
Conclusions:
- Targeting intracellular signaling pathways is a viable and evolving strategy in cancer therapy.
- Further research and development are needed to overcome challenges in this therapeutic area.
- This approach holds potential for more effective and less toxic cancer treatments.